RECRUITING

The K-Map Study, Global Prevalence of KC

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Keratoconus is a ocular disease classified under ectatic diseases which often results in bilateral and asymmetrical corneal distortion. It usually affects patients at young age and can cause severe visual loss. The overall goal of this study is to assess the prevalence of keratoconus (KC) in children and adolescents in various regions of the world based on modern tomographic imaging methods, and to verify whether the occurrence rates reported from literature should be corrected. Our hypothesis is that the prevalence of the disease is much higher than that traditionally reported. At each site, corneal tomography examinations (Pentacam) will be performed bilaterally in children and adolescents, who are not ill or with any ophthalmological symptom. The population to be studied will be composed of children and adolescents on medical visits for non-ophthalmologic reasons, aged between 6 and 20 years. Multiple cities, from different continents (North America, South America, Asia and Europe) will participate.

Official Title

The K-Map Study, Global Prevalence of KC

Quick Facts

Study Start:2015-12-28
Study Completion:2025-02-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03115710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Years to 23 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male or female, 6-23 years of age.
  2. * Subjects seen for a non-ophthalmic appointment
  3. * Provide signed and dated patient consent form (signed by parents / legal guardians).
  4. * Willing to comply with all study procedures and be available for the duration of the study
  1. * Patients with a preexisting ocular disease / condition
  2. * Pregnancy or breastfeeding

Contacts and Locations

Study Contact

Farhad Hafezi, MDPhD
CONTACT
+41 44 741 81 81
fhafezi@elza-institute.com

Principal Investigator

Farhad Hafezi
STUDY_DIRECTOR
ELZA Institute

Study Locations (Sites)

USC Roski Eye Institute
Los Angeles, California, 90033
United States

Collaborators and Investigators

Sponsor: University Hospital, Geneva

  • Farhad Hafezi, STUDY_DIRECTOR, ELZA Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-12-28
Study Completion Date2025-02-01

Study Record Updates

Study Start Date2015-12-28
Study Completion Date2025-02-01

Terms related to this study

Keywords Provided by Researchers

  • Keratoconus
  • Prevalence

Additional Relevant MeSH Terms

  • Keratoconus